AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1137011 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ipsilateral trial
Number of subjects: 30
Study 1137011 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral contralateral trial
Number of subjects: 30
Study 1137011 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral trial
Number of subjects: 30
Study 31744374 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus self-sampling kit
Number of subjects: 116
Study 31760819 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation of AF
Number of subjects: 140
Study 31760819 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (BMT)
Number of subjects: 140
Study 28026849 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of fabella (unilateral or bilateral)
Number of subjects: 500
Study 28026849 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of fabella by body side
Number of subjects: 500
Study 28026849 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of fabella by gender
Number of subjects: 500
Study 28026849 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of fabella by age groups
Number of subjects: 500
Study 26439038 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal suppositories (400 mg, 200 mg 2 times per day) + Alpha Lipoic Acid (ALA) (600 mg, 300 mg 2 times per day)
Number of subjects: 19
Study 26439038 — intervention group
Group type: COMPARATOR
Intervention: Progesterone vaginal suppositories (400 mg, 200 mg 2 times per day)
Number of subjects: 19
Study 23504821 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane (EVE + EXE)
Number of subjects: 0
Study 23504821 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus exemestane (PBO + EXE)
Number of subjects: 0
Study 21070328 — intervention group
Group type: EXPERIMENTAL
Intervention: IPI implants
Number of subjects: 64
Study 21070328 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐Plant implants
Number of subjects: 64
Study 21070328 — intervention group
Group type: COMPARATOR
Intervention: Both implant systems (IPI and I‐Plant)
Number of subjects: 64
Study 21070328 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional implants with good primary stability
Number of subjects: 64
Study 21070328 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stability
Number of subjects: 64
Study 21070328 — intervention group
Group type: COMPARATOR
Intervention: Gender, kind of superstructure, location of the implant, tooth status of the opposing jaw, immediate prosthetic superstructure
Number of subjects: 64
Study 19942103 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available magnetic wrist strap
Number of subjects: 45
Study 19942103 — intervention group
Group type: COMPARATOR
Intervention: Weak magnetic wrist strap
Number of subjects: 45
Study 19942103 — intervention group
Group type: COMPARATOR
Intervention: Demagnetised wrist strap
Number of subjects: 45
Study 19942103 — intervention group
Group type: COMPARATOR
Intervention: Copper bracelet
Number of subjects: 45
Study 17273661 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (300 mg daily for 30 days)
Number of subjects: 44
Study 17273661 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline (1.2 g daily for 30 days)
Number of subjects: 44
Study 15111077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon Achilles lengthening (TAL)
Number of subjects: 28
Study 15111077 — intervention group
Group type: COMPARATOR
Intervention: Total contact casting (TCC)
Number of subjects: 28
Study 11434591 — intervention group
Group type: EXPERIMENTAL
Intervention: Active coeliac disease (mean anti‐tTG, 21 AU)
Number of subjects: 1182
Study 11434591 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated coeliac disease (mean anti‐tTG, 5 AU)
Number of subjects: 1182
Study 11434591 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (mean anti‐tTG, 3 AU)
Number of subjects: 1182
Study 11434591 — intervention group
Group type: EXPERIMENTAL
Intervention: Eu‐tTG assay
Number of subjects: 1182
Study 9534995 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccines
Number of subjects: 0
Study 9534995 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose at 1 year of age
Number of subjects: 0
Study 7723004 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment battery used in Project MATCH
Number of subjects: 0
Study 7723004 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies employed in Project MATCH
Number of subjects: 0
Study 7723004 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of assessment measures
Number of subjects: 0
Study 2845707 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 5000 anti-XaU injected every 24 hours
Number of subjects: 215
Study 2845707 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) 5000 IU injected every 12 hours
Number of subjects: 215
Study 1097977 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 (PGE2)
Number of subjects: 56
Study 1097977 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 30366741 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1.5 carbohydrate‐protein supplement (16g CHO/25g PRO) pre-training (PRE)
Number of subjects: 43
Study 30366741 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1.5 carbohydrate‐protein supplement (16g CHO/25g PRO) post-training (POST)
Number of subjects: 43
Study 30366741 — intervention group
Group type: COMPARATOR
Intervention: No supplement (CON)
Number of subjects: 43
Study 29468530 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-guided therapy using NT-proBNP
Number of subjects: 0
Study 29468530 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27886777 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation attempted or continued by Emergency Medical Service staff
Number of subjects: 11451
Study 27886777 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation withheld due to futility
Number of subjects: 11451
Study 27886777 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation withheld due to signs unequivocally associated with death
Number of subjects: 11451
Study 27886777 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation withheld due to do-not-attempt-resuscitation decision
Number of subjects: 11451
Study 27886777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander CPR rates
Number of subjects: 11451
Study 24841833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg once daily via HandiHaler
Number of subjects: 457
Study 24841833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 21964557 — intervention group
Group type: EXPERIMENTAL
Intervention: Leftward optokinetic stimulation (OKS) during an auditory midline task.
Number of subjects: 20
Study 21964557 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive leftward optokinetic stimulation (OKS) with smooth pursuit eye movements as therapy.
Number of subjects: 20
Study 21964557 — intervention group
Group type: COMPARATOR
Intervention: Visual scanning therapy.
Number of subjects: 20
Study 20659879 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest Pain Unit (CPU) care
Number of subjects: 2389
Study 20659879 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 2389
Study 17559376 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion for 12 hours (SOM1)
Number of subjects: 3130
Study 17559376 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin bolus (SOM3)
Number of subjects: 3130
Study 17559376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate infusion for 12 hours (GAB1)
Number of subjects: 3130
Study 17559376 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin infusion for less than 12 hours (SOM2)
Number of subjects: 3130
Study 17559376 — intervention group
Group type: COMPARATOR
Intervention: Gabexate infusion for less than 12 hours (GAB2)
Number of subjects: 3130
Study 16269290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatoduodenectomy with extended lymphadenectomy (PD/ELND)
Number of subjects: 132
Study 16269290 — intervention group
Group type: COMPARATOR
Intervention: Standard pancreatoduodenectomy (PD)
Number of subjects: 132
Study 12127377 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training programme over 6 weeks (n=15)
Number of subjects: 25
Study 12127377 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 25
Study 10597956 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplement (2.5 mg or 1.0 mg)
Number of subjects: 14021
Study 10597956 — intervention group
Group type: COMPARATOR
Intervention: No folic acid supplement
Number of subjects: 14021
Study 8598594 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (one of four regimens: streptokinase with subcutaneous heparin; streptokinase with intravenous heparin; streptokinase plus alteplase with intravenous heparin; accelerated alteplase with intravenous heparin)
Number of subjects: 41021
Study 8598594 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (alteplase)
Number of subjects: 41021
Study 8598594 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 41021
Study 2303145 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (MPA)
Number of subjects: 48
Study 2303145 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone (NET)
Number of subjects: 48
Study 2303145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6113192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bd
Number of subjects: 103
Study 6113192 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 200 mg tds and 400 mg nocte
Number of subjects: 103
Study 31126541 — intervention group
Group type: EXPERIMENTAL
Intervention: Salix extract (400 mg daily)
Number of subjects: 96
Study 31126541 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid (750 mg daily)
Number of subjects: 96
Study 27819804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Subtraction Meditation (MSM)
Number of subjects: 46
Study 27819804 — intervention group
Group type: COMPARATOR
Intervention: Self-management education (SME)
Number of subjects: 46
Study 26482774 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual school-based deworming (SBD)
Number of subjects: 0
Study 26482774 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual community-based deworming (CBD)
Number of subjects: 0
Study 26482774 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual community-based deworming (CBD)
Number of subjects: 0
Study 26482774 — intervention group
Group type: COMPARATOR
Intervention: Annual SBD
Number of subjects: 0
Study 26482774 — intervention group
Group type: COMPARATOR
Intervention: Annual CBD
Number of subjects: 0
Study 26482774 — intervention group
Group type: COMPARATOR
Intervention: Biannual CBD
Number of subjects: 0
Study 26482774 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 25052890 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of folic acid added to ADM for 12 weeks
Number of subjects: 475
Study 25052890 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to ADM for 12 weeks
Number of subjects: 475
Study 23171320 — intervention group
Group type: EXPERIMENTAL
Intervention: IFCR‐L (Intermittent fasting combined with calorie restriction and liquid diet)
Number of subjects: 54
Study 23171320 — intervention group
Group type: COMPARATOR
Intervention: IFCR‐F (Intermittent fasting combined with calorie restriction and food diet)
Number of subjects: 54
Study 23171320 — intervention group
Group type: EXPERIMENTAL
Intervention: IFCR‐L
Number of subjects: 54
Study 23171320 — intervention group
Group type: COMPARATOR
Intervention: IFCR‐F
Number of subjects: 54
Study 20951300 — intervention group
Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (WMTA) at pH 8.4
Number of subjects: 80
Study 20951300 — intervention group
Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (WMTA) at pH 10.4
Number of subjects: 80
Study 17967379 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 0
Study 17967379 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 0
Study 16304073 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 9978
Study 16304073 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 9978
Study 16304073 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (consistent therapy)
Number of subjects: 9978
Study 16304073 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (consistent therapy)
Number of subjects: 9978
Study 11967499 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 157
Study 11967499 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 157
Study 11967499 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg
Number of subjects: 157
Study 11967499 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus medroxyprogesterone acetate (MPA) 2.5 mg
Number of subjects: 157
Study 11967499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 9815234 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐6 reactivation
Number of subjects: 53
Study 9815234 — intervention group
Group type: COMPARATOR
Intervention: CMVIG prophylaxis
Number of subjects: 53
Study 7716850 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound
Number of subjects: 9
Study 7716850 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray-scale ultrasound
Number of subjects: 9
Study 2654254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (Atarax; Roerig, New York, N.Y.)
Number of subjects: 8
Study 2654254 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen (Zaditen; Sandoz Pharmaceuticals, Basel, Switzerland)
Number of subjects: 8
Study 6109503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer Lactate (Group A)
Number of subjects: 0
Study 6109503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 60,000 (Group B)
Number of subjects: 0
Study 6109503 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study 31728628 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-plasma filtration (PF)
Number of subjects: 16
Study 31728628 — intervention group
Group type: COMPARATOR
Intervention: Prior to PF
Number of subjects: 16
Study 30500464 — intervention group
Group type: EXPERIMENTAL
Intervention: w‐SPIINA (web‐based Spine Platform featuring Interaction and Information by Animation)
Number of subjects: 114
Study 30500464 — intervention group
Group type: COMPARATOR
Intervention: Standard information regimen (Control)
Number of subjects: 114
Study 28241154 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 249
Study 28241154 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 249
Study 28241154 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 249
Study 28241154 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture vs Sham acupuncture
Number of subjects: 249
Study 28241154 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture vs Waiting-list
Number of subjects: 249
Study 28241154 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture vs Waiting-list
Number of subjects: 249
Study 26028120 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued methadone treatment
Number of subjects: 283
Study 26028120 — intervention group
Group type: COMPARATOR
Intervention: Forced withdrawal from methadone (usual care)
Number of subjects: 283
Study 23447518 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) therapy
Number of subjects: 14
Study 23447518 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 20878497 — intervention group
Group type: EXPERIMENTAL
Intervention: Language-concordant physicians
Number of subjects: 510
Study 20878497 — intervention group
Group type: EXPERIMENTAL
Intervention: Language-discordant physicians
Number of subjects: 510
Study 20878497 — intervention group
Group type: COMPARATOR
Intervention: Latino English speakers
Number of subjects: 510
Study 20878497 — intervention group
Group type: COMPARATOR
Intervention: LEP patients with language-concordant physicians vs Latino English speakers
Number of subjects: 510
Study 20878497 — intervention group
Group type: COMPARATOR
Intervention: LEP patients with language-discordant physicians vs Latino English speakers
Number of subjects: 510
Study 20878497 — intervention group
Group type: EXPERIMENTAL
Intervention: LEP patients with language-discordant physicians
Number of subjects: 510
Study 19940325 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute arm-cycling exercise
Number of subjects: 11
Study 19133062 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of diclofenac (30 mg total from two tapes)
Number of subjects: 14
Study 19133062 — intervention group
Group type: COMPARATOR
Intervention: Oral application of diclofenac (37.5 mg capsule)
Number of subjects: 14
Study 16400897 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg daily)
Number of subjects: 7241
Study 16400897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7241
Study 12468570 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg/d
Number of subjects: 20
Study 12468570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (escalated to 10 mg/d)
Number of subjects: 20
Study 12468570 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (escalated to 100 mg/d)
Number of subjects: 20
Study 9396874 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional factor images
Number of subjects: 0
Study 9396874 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzzy ROI curves
Number of subjects: 0
Study 8684896 — intervention group
Group type: EXPERIMENTAL
Intervention: S2 stimuli Category C (semantically and physically different from S1)
Number of subjects: 0
Study 8684896 — intervention group
Group type: EXPERIMENTAL
Intervention: S2 stimuli Category B (semantically the same but physically different from S1)
Number of subjects: 0
Study 8684896 — intervention group
Group type: COMPARATOR
Intervention: S2 stimuli Category A (the same as S1)
Number of subjects: 0
Study 2483124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood temperature of 20 degrees C
Number of subjects: 20
Study 2483124 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative blood temperature of 28 degrees C
Number of subjects: 20
Study 326261 — intervention group
Group type: EXPERIMENTAL
Intervention: Piprozoline (Problin) therapy
Number of subjects: 1545
Study 326261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1545
Study 14622809 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% sucrose
Number of subjects: 130
Study 14622809 — intervention group
Group type: EXPERIMENTAL
Intervention: breast milk
Number of subjects: 130
Study 14622809 — intervention group
Group type: EXPERIMENTAL
Intervention: sterile water
Number of subjects: 130
Study 14622809 — intervention group
Group type: EXPERIMENTAL
Intervention: breast-feeding
Number of subjects: 130
Study 30877773 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria/tetanus vaccination
Number of subjects: 284
Study 29043904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) as inhalant anesthesia
Number of subjects: 86
Study 29043904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitrous oxide)
Number of subjects: 86
Study 27861344 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 2165
Study 27861344 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus IFL
Number of subjects: 2165
Study 27861344 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI or IFL alone
Number of subjects: 2165
Study 24520783 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingyi Chengqi Decoction (QCD)
Number of subjects: 86
Study 24520783 — intervention group
Group type: COMPARATOR
Intervention: Routine Western medicine (Control)
Number of subjects: 86
Study 22582872 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg Loperamide (LOP)
Number of subjects: 18
Study 22582872 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg Loperamide (LOP) + 125 mg Simethicone (SIM)
Number of subjects: 18
Study 22582872 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 18
Study 20399022 — intervention group
Group type: EXPERIMENTAL
Intervention: Swing shift
Number of subjects: 19
Study 20399022 — intervention group
Group type: COMPARATOR
Intervention: 14 consecutive night shifts
Number of subjects: 19
Study 17538178 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging technologies for detection, characterization, and treatment of colorectal cancer
Number of subjects: 0
Study 17538178 — intervention group
Group type: EXPERIMENTAL
Intervention: Biology-directed laboratory investigations
Number of subjects: 0
Study 16091274 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere
Number of subjects: 1
Study 16091274 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere
Number of subjects: 1
Study 11830809 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic‐assisted reduction and percutaneous cannulated screw fixation
Number of subjects: 5
Study 10442280 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP with a thick loop
Number of subjects: 36
Study 10442280 — intervention group
Group type: COMPARATOR
Intervention: TURP with a standard loop
Number of subjects: 36
Study 7842199 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilator (isoproterenol)
Number of subjects: 5887
Study 7842199 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge test
Number of subjects: 5887
Study 7842199 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors indicating intrinsic airway reactivity
Number of subjects: 5887
Study 7842199 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of spirometry testing factors
Number of subjects: 5887
Study 2240505 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine 3 mg/kg
Number of subjects: 100